The antiviral drug Lenacapavir, from the pharmaceutical company Gilead, has managed to prevent 100% of AIDS infections in women with a dose of two injections per year.

The PURPOSE 1 study was conducted out only in women because they represent a significant proportion of new HIV infections in many regions of the world, especially in sub-Saharan Africa.

The results of the trial, carried out on women in South Africa and Uganda, were presented at the 25th International AIDS Conference in Munich last July and have been published in The New England Journal of Medicine.

For the moment, the main drawback is its high price, since two doses cost 20,221.5 euros in Europe and $42,000 in the United States.

Gilead will not initiate the drug approval process until the results of the PURPOSE 2 trial are known, which are expected in late 2024 or early 2025.

A new HIV patient cured

Another important piece of news is that during the International AIDS Conference, the case of a new patient, the seventh, who has been cured of the disease was also presented.

The patient, known as the “second Berlin patient”, had been suffering from HIV since 2009 and was diagnosed with acute myeloid leukaemia in 2015. As treatment for this disease, he received chemotherapy and a stem cell transplant.

This is the second time that a patient at the Charité hospital in Berlin has been cured of HIV. In 2009, the “Berlin patient” became the first person in the world to be cured of HIV thanks to a stem cell transplant.

So far, stem cell transplants have only been successful in eliminating the virus from the body in exceptional cases. This type of transplant is an option for patients who, in addition to suffering from HIV, also develop leukemia or lymphoma.

In this procedure, stem cells from a healthy person are transferred to the patient, replacing the affected cells in his bone marrow and promoting a restoration of his immune system.

In order to multiply, HIV enters several immune cells, for which it requires a receptor called CCR5. Around 1% of the European population suffers from a mutation in the gene responsible for the synthesis of this receptor, known as delta 32. This mutation prevents the virus from entering the cell, which makes people who suffer from it immune to HIV.

If a stem cell donor carries this mutation, the transfer of these cells into the marrow of an HIV patient can regenerate it, causing a cure not only of their leukemia or lymphoma, but also of the HIV infection.

A team from the Charité hospital demonstrated the effectiveness of this procedure in 2008 when it was applied to the “Berlin patient.”

The second time this hospital has treated a patient with acute myeloid leukemia and HIV, they have used a slightly different approach.

The risk profile of the second Berlin patient meant that he underwent both chemotherapy and a stem cell transplant.

“We couldn’t find a matching stem cell donor who was immune to HIV, but we did manage to find one whose cells have two versions of the CCR5 receptor: the normal one, and then an extra, mutated one,” stated Olaf Penack, a senior physician at the department treating the patient.

Although the donor was not immune, the stem cell transplant cured the patient’s HIV, and he stopped taking antiviral treatment in 2018.

The case of the second “Berlin patient” shows that it is possible to cure HIV even though there is a functional receptor that the virus can use.

Prof. Gaebler, expert on HIV and research group leader at the Department of Infectious Diseases and Critical Care Medicine at Charité explains that “this means the fact that the virus was cured is apparently not attributable to the donor’s genetic CCR5 receptor, but instead to the fact that her transplanted immune cells eliminated all of the patient’s HIV-infected cells”. “By replacing his immune system, we apparently destroyed all the places where the virus was hiding, so it was no longer able to infect the new immune cells from the donor.”

Researchers hope that investigating the mechanism by which HIV was cured in the second Berlin patient will lead to new insights for future treatment of people with HIV.

Before undergoing the stem cell transplant, the second Berlin patient was among the 16% of people of European origin who, like the stem cell donor, carry both the healthy version and a mutated version of the CCR5 receptor in their cells.

Background

To date, five cases of HIV cure have been reported in people who received stem cell transplants from donors with the delta 32 genetic mutation in the CCR5 receptor.

The mutation is homozygous if it is present in both copies of the gene and heterozygous if it is present in only one copy. Altering the CCR5 receptor prevents the virus from infecting immune system cells.

Other HIV patients who received stem cells from donors without the delta 32 m

utation experienced viral rebound when they stopped antiretroviral treatment.

A recent article published in the prestigious journal Nature Medicine reports the case of a man with a durable remission of HIV after a stem cell transplant from a donor without the delta 32 mutation in the CCR5 receptor to treat an extramedullary myeloid tumor.

For the time being, in this patient the plasma viral load has remained undetectable for 32 months after discontinuation of antiretroviral therapy. The absence of viral rebound has also been corroborated.

These results suggest that HIV remission could also be achieved with non-mutant CCR5 stem cell transplantation.

Bioethical assessment

Advances in the treatment of a disease such as AIDS have succeeded in turning a fatal disease into a chronic one, reducing the viral load of those infected to undetectable levels thanks to the widespread use of antiretrovirals.

According to UNAIDS, HIV has infected 88.4 million people since the beginning of the epidemic and has caused 42.3 million deaths from AIDS-related illnesses.

New advances in stem cell therapies offer hope for a definitive cure for this infection, although their widespread use still requires a lot of effort. Specifically in the improvement of these techniques and in making their cost affordable for the health services and extending them to all those affected.

In the future, it may be possible to genetically edit the stem cells of compatible donors to modify the gene responsible for producing the CCR5 receptor, the gateway for the AIDS virus to enter the body. The possibilities of genetic editing in this field are enormous, although still limited by its effectiveness, safety and current high cost.

Efforts must be made by researchers and their financial backers to advance the improvement and safe application of these new therapeutic possibilities. But we must not forget that the AIDS epidemic affects more dramatically the most disadvantaged regions, which are currently unable to afford the cost of these treatments.

The development of policies that promote this research and allow access to these therapies on equal terms, allocating funds to reduce the cost of related processes, constitutes a health priority and a bioethical requirement.

Julio Tudela and Ester Bosch

Bioethics Observatory – Institute of Life Sciences

Catholic University of Valencia

Share This Story, Choose Your Platform!